1. Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide;Badros;Blood,2000
2. Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients;Barlogie;Blood,2001a
3. Thalidomide in the management of multiple myeloma;Barlogie;Seminars in Hematology,2001b
4. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies;Bellamy;Cancer Research,1999
5. High incidence of thalidomide-associated deep vein thrombosis and pulmonary emboli when chemotherapy is also administered;Bennett;Blood,2001